Rapid Neurological Recovery Post Thrombolysis: Mechanisms and Implications


Intravenous thrombolysis improves long term functional outcomes in acute ischemic stroke. A select proportion of patients treated with thrombolysis experience rapid early neurological recovery, a powerful predictor of favourable long term outcomes. There is increased interest to augment early neurological recovery by endovascular therapy or by adjuvant intravenous thrombolytics. However, incomplete understanding of the physiological mechanisms of early recovery has hampered a unified approach to monitor and to triage patients for invasive therapy. This review aims to examine the current understanding and insights gained from recent studies concerning early recovery and to inform the design of future studies.

Share and Cite:

Machumpurath, B. , Reddy, M. and Yan, B. (2013) Rapid Neurological Recovery Post Thrombolysis: Mechanisms and Implications. Neuroscience and Medicine, 4, 36-44. doi: 10.4236/nm.2013.41006.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Davalos, D. Guidetti, et al., “Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke,” The New England Journal of Medicine, Vol. 359, No. 13, 2008, pp. 1317-1329. doi:10.1056/NEJMoa0804656
[2] The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, “Tissue Plasminogen Activator for Acute Ischemic Stroke,” The New England Journal of Medicine, Vol. 333, No. 24, 1995, pp. 1581-1587. doi:10.1056/NEJM199512143332401
[3] N. Wahlgren, N. Ahmed, A. Davalos, G. A. Ford, M. Grond, W. Hacke, et al., “Thrombolysis with Alteplase for Acute Ischaemic Stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An Observational Study,” Lancet, Vol. 369, No. 9558, 2007, pp. 275-282. doi:10.1016/S0140-6736(07)60149-4
[4] W. Hacke, M. Kaste, C. Fieschi, R. von Kummer, A. Davalos, D. Meier, et al., “Randomised Double-Blind Placebo-Controlled Trial of Thrombolytic Therapy with Intravenous Alteplase in Acute Ischaemic Stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators,” Lancet, Vol. 352, No. 9136, 1998, pp. 1245-1251. doi:10.1016/S0140-6736(98)08020-9
[5] P. Sandercock, J. M. Wardlaw, R. I. Lindley, M. Dennis, G. Cohen, G. Murray, et al., “The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the Third International Stroke Trial [IST-3]): A Randomised Controlled Trial,” Lancet, Vol. 379, No. 9834, 2012, pp. 2352-2363. doi:10.1016/S0140-6736(12)60768-5
[6] D. L. Brown, K. C. Johnston, D. P. Wagner and E. C. Haley Jr., “Predicting Major Neurological Improvement with Intravenous Recombinant Tissue Plasminogen Activator Treatment of Stroke,” Stroke, Vol. 35, No. 1, 2004, pp. 147-150. doi:10.1161/01.STR.0000105396.93273.72
[7] B. Machumpurath, S. M. Davis and B. Yan, “Rapid Neurological Recovery after Intravenous Tissue Plasminogen Activator in Stroke: Prognostic Factors and Outcome,” Cerebrovascular Disease, Vol. 31, No. 3, 2010, pp. 278-283. doi:10.1159/000322564
[8] P. A. Dharmasaroja, S. Muengtaweepongsa and P. Dharmasaroja, “Early Outcome after Intravenous Thrombolysis in Patients with Acute Ischemic Stroke,” Neurology India, Vol. 59, No. 3, 2011, pp. 351-354. doi:10.4103/0028-3886.82723
[9] G. Saposnik, S. Di Legge, F. Webster and V. Hachinski, “Predictors of Major Neurologic Improvement after Thrombolysis in Acute Stroke,” Neurology, Vol. 65, No. 8, 2005, pp. 1169-1174. doi:10.1212/01.wnl.0000180687.75907.4b
[10] T. Kharitonova, R. Mikulik, R. O. Roine, L. Soinne, N. Ahmed and N. Wahlgren, “Association of Early National Institutes of Health Stroke Scale Improvement with Vessel Recanalization and Functional Outcome after Intravenous Thrombolysis in Ischemic Stroke,” Stroke, Vol. 42, No. 6, 2011, pp. 1638-1643. doi:10.1161/STROKEAHA.110.606194
[11] I. P. Muresan, P. Favrole, P. Levy, F. Andreux, B. Marro and S. Alamowitch, “Very Early Neurologic Improvement after Intravenous Thrombolysis,” Archives of Neurology, Vol. 67, No. 11, 2010, pp. 1323-1328. doi:10.1001/archneurol.2010.265
[12] D. B. Boddu, V. C. Srinivasarao Bandaru, P. G. Reddy, M. Madhusudan, M. K. Rukmini, T. Suryaprabha, et al., “Predictors of Major Neurological Improvement after Intravenous Thrombolysis in Acute Ischemic Stroke: A Hospital-Based Study from South India,” Neurology India, Vol. 58, No. 3, 2010, pp. 403-406. doi:10.4103/0028-3886.66085
[13] H. S. Nam, K. Y. Lee, S. W. Han, S. H. Kim, J. Y. Lee, S. H. Ahn, et al., “Prediction of Long-Term Outcome by Percent Improvement after the First Day of Thrombolytic Treatment in Stroke Patients,” Journal of the Neurological Sciences, Vol. 281, No. 1-2, 2009, pp. 69-73. doi:10.1016/j.jns.2009.02.365
[14] R. A. Felberg, N. J. Okon, A. El-Mitwalli, W. S. Burgin, J. C. Grotta and A. V. Alexandrov, “Early Dramatic Recovery during Intravenous Tissue Plasminogen Activator Infusion: Clinical Pattern and Outcome in Acute Middle Cerebral Artery Stroke,” Stroke, Vol. 33, No. 5, 2002, pp. 1301-1307. doi:10.1161/01.STR.0000015556.48283.74
[15] S. M. Davis, G. A. Donnan, M. W. Parsons, C. Levi, K. S. Butcher, A. Peeters, et al. “Effects of Alteplase beyond 3 h after Stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A Placebo-Controlled Randomised Trial,” Lancet Neurology, Vol. 7, No. 4, 2008, pp. 299-309. doi:10.1016/S1474-4422(08)70044-9
[16] G. W. Albers, V. N. Thijs, L. Wechsler, S. Kemp, G. Schlaug, E. Skalabrin, et al., “Magnetic Resonance Imaging Profiles Predict Clinical Response to Early Reperfusion: The Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study,” Annals of Neurology, Vol. 60, No. 5, 2006, pp. 508-517. doi:10.1002/ana.20976
[17] A. R. Young, O. Touzani, J. M. Derlon, G. Sette, E. T. MacKenzie and J. C. Baron, “Early Reperfusion in the Anesthetized Baboon Reduces Brain Damage Following Middle Cerebral Artery Occlusion: A Quantitative Analysis of Infarction Volume,” Stroke, Vol. 28, No. 3, 1997, pp. 632-637. doi:10.1161/01.STR.28.3.632
[18] D. A. De Silva, J. N. Fink, S. Christensen, M. Ebinger, C. Bladin, C. R. Levi, et al., “Assessing Reperfusion and Recanalization as Markers of Clinical Outcomes after Intravenous Thrombolysis in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET),” Stroke, Vol. 40, No. 8, 2009, pp. 2872-2874. doi:10.1161/STROKEAHA.108.543595
[19] W. D. Heiss, M. Grond, A. Thiel, H. M. von Stockhausen, J. Rudolf, M. Ghaemi, et al., “Tissue at Risk of Infarction Rescued by Early Reperfusion: A Positron Emission Tomography Study in Systemic Recombinant Tissue Plasminogen Activator Thrombolysis of Acute Stroke,” Journal of Cerebral Blood Flow & Metabolism, Vol. 18, No. 12, 1998, pp. 1298-1307. doi:10.1097/00004647-199812000-00004
[20] L. A. Labiche, M. Malkoff and A. V. Alexandrov, “Residual Flow Signals Predict Complete Recanalization in Stroke Patients Treated with TPA,” Journal of Neuroimaging, Vol. 13, No. 1, 2003, pp. 28-33.
[21] M. T. Wunderlich, M. Goertler, T. Postert, E. Schmitt, G. Seidel, G. Gahn, et al., “Recanalization after Intravenous Thrombolysis: Does a Recanalization Time Window Exist?” Neurology, Vol. 68, No. 17, 2007, pp. 1364-1368. doi:10.1212/01.wnl.0000260604.26469.8e
[22] J. H. Rha and J. L. Saver, “The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis,” Stroke, Vol. 38, No. 3, 2007, pp. 967-973. doi:10.1161/01.STR.0000258112.14918.24
[23] E. Mori, Y. Yoneda, M. Tabuchi, T. Yoshida, S. Ohkawa, Y. Ohsumi, et al., “Intravenous Recombinant Tissue Plasminogen Activator in Acute Carotid Artery Territory Stroke,” Neurology, Vol. 42, No. 5, 1992, pp. 976-982. doi:10.1212/WNL.42.5.976
[24] G. J. del Zoppo and J. A. Koziol, “Recanalization and Stroke Outcome,” Circulation, Vol. 115, No. 20, 2007, pp. 2602-2605. doi:10.1161/CIRCULATIONAHA.107.698225
[25] T. Neumann-Haefelin, R. du Mesnil de Rochemont, J. B. Fiebach, A. Gass, C. Nolte, T. Kucinski, et al., “Effect of Incomplete (Spontaneous and Postthrombolytic) Recanalization after Middle Cerebral Artery Occlusion: A Magnetic Resonance Imaging Study,” Stroke, Vol. 35, No. 1, 2004, pp. 109-114. doi:10.1161/01.STR.0000106482.31425.D1
[26] R. Bhatia, M. D. Hill, N. Shobha, B. Menon, S. Bal, P. Kochar, et al., “Low Rates of Acute Recanalization with Intravenous Recombinant Tissue Plasminogen Activator in Ischemic Stroke: Real-World Experience and a Call for Action,” Stroke, Vol. 41, No. 10, 2010, pp. 2254-2258. doi:10.1161/STROKEAHA.110.592535
[27] L. A. Labiche, F. Al-Senani, A. W. Wojner, J C. Grotta, M. Malkoff and A. V. Alexandrov, “Is the Benefit of Early Recanalization Sustained at 3 Months? A Prospective Cohort Study,” Stroke, Vol. 34, No. 3, 2003, pp. 695-698. doi:10.1161/01.STR.0000055940.00316.6B
[28] I. Christou, A. V. Alexandrov, W. S. Burgin, A. W. Wojner, R. A. Felberg, M. Malkoff, et al., “Timing of Recanalization after Tissue Plasminogen Activator Therapy Determined by Transcranial Doppler Correlates with Clinical Recovery from Ischemic Stroke,” Stroke, Vol. 31, No. 8, 2000, pp. 1812-1816. doi:10.1161/01.STR.31.8.1812
[29] G. A. Christofordis, Y. Mohammad, M. Yang, C. Louis, A. Slivka, et al., “Factors Associated with a ‘Lazarus Phenomenon’ 24 Hours Following Intraarterial Thrombolytic Therapy in Acute Ischemic Stroke,” International Stroke Conference, San Francisco, 7-9 February 2007.
[30] H. Kawano, T. Hirano, Y. Inatomi, T. Terasaki, T. Yonehara and M. Uchino, “Presence of Deep White Matter Lesions on Diffusion-Weighted Imaging Is a Negative Predictor of Early Dramatic Improvement after Intravenous Tissue Plasminogen Activator Thrombolysis,” Cerebrovascular Disease, Vol. 30, No. 3, 2010, pp. 230-236. doi:10.1159/000317183
[31] A. V. Alexandrov, R. A. Felberg, A. M. Demchuk, I. Christou, W. S. Burgin, M. Malkoff, et al., “Deterioration Following Spontaneous Improvement: Sonographic Findings in Patients with Acutely Resolving Symptoms of Cerebral Ischemia,” Stroke, Vol. 31, No. 4, 2000, pp. 915-919. doi:10.1161/01.STR.31.4.915
[32] V. Rajajee, C. Kidwell, S. Starkman, B. Ovbiagele, J. R. Alger, P. Villablanca, et al., “Early MRI and Outcomes of Untreated Patients with Mild or Improving Ischemic Stroke,” Neurology, Vol. 67, No. 6, 2006, pp. 980-984. doi:10.1212/01.wnl.0000237520.88777.71
[33] A. V. Alexandrov, C. E. Hall, L. A. Labiche, A. W. Wojner and J. C. Grotta, “Ischemic Stunning of the Brain: Early Recanalization without Immediate Clinical Improvement in Acute Ischemic Stroke,” Stroke, Vol. 35, No. 2, 2004, pp. 449-452. doi:10.1161/01.STR.0000113737.58014.B4
[34] W. S. Smith, G. Sung, J. Saver, R. Budzik, G. Duckwiler, D. S. Liebeskind, et al., “Mechanical Thrombectomy for Acute Ischemic Stroke: Final Results of the Multi MERCI Trial,” Stroke, Vol. 39, No. 4, 2008, pp. 1205-1212. doi:10.1161/STROKEAHA.107.497115
[35] The Penumbra Pivotal Stroke Trial Investigators, “The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease,” Stroke, Vol. 40, No. 8, 2009, pp. 2761-2768. doi:10.1161/STROKEAHA.108.544957
[36] C. A. Molina and J. Alvarez-Sabin, “Recanalization and Reperfusion Therapies for Acute Ischemic Stroke,” Cerebrovascular Disease, Vol. 27, No. 1, 2009, pp. 162-167. doi:10.1159/000200455
[37] P. Khatri, J. Neff, J. P. Broderick, J. C. Khoury, J. Carrozzella and T. Tomsick, “Revascularization End Points in Stroke Interventional Trials: Recanalization versus Reperfusion in IMS-I,” Stroke, Vol. 36, No. 11, 2005, pp. 2400-2403. doi:10.1161/01.STR.0000185698.45720.58
[38] G. A. Christoforidis, Y. Mohammad, D. Kehagias, B. Avutu and A. P. Slivka, “Angiographic Assessment of Pial Collaterals as a Prognostic Indicator Following IntraArterial Thrombolysis for Acute Ischemic Stroke,” American Journal of Neuroradiology, Vol. 26, No. 7, 2005, pp. 1789-1797.
[39] D. S. Liebeskind, D. Kim, S. Starkman, K. Changizi, A. G. Ohanian, R. Jahan, et al., “Collateral Failure? Late Mechanical Thrombectomy after Failed Intravenous Thrombolysis,” Journal of Neuroimaging, Vol. 20, No. 1, 2008, pp. 78-82. doi:10.1111/j.1552-6569.2008.00295.x
[40] M. G. Lansberg, M. Straka, S. Kemp, M. Mlynash, L. R. Wechsler, T. G. Jovin, et al., “MRI Profile and Response to Endovascular Reperfusion after Stroke (DEFUSE 2): A Prospective Cohort Study,” Lancet Neurology, Vol. 11, No. 10, 2012, pp. 860-867. doi:10.1016/S1474-4422(12)70203-X
[41] R. Bolli and E. Marban, “Molecular and Cellular Mechanisms of Myocardial Stunning,” Physiological Reviews, Vol. 79, No. 2, 1999, pp. 609-634.
[42] H. Luss, M. Schafers, J. Neumann, D. Hammel, C. Vahlhaus, H. A. Baba, et al., “Biochemical Mechanisms of Hibernation and Stunning in the Human Heart,” Cardiovascular Research, Vol. 56, No. 3, 2002, pp. 411-421. doi:10.1016/S0008-6363(02)00596-5
[43] R. von Kummer, H. Bourquain, S. Bastianello, L. Bozzao, C. Manelfe, D. Meier, et al., “Early Prediction of Irreversible Brain Damage after Ischemic Stroke at CT,” Radiology, Vol. 219, No. 1, 2001, pp. 95-100.
[44] D. Uematsu, J. H. Greenberg, M. Reivich and W. F. Hickey, “Direct Evidence for Calcium-Induced Ischemic and Reperfusion Injury,” Annals of Neurology, Vol. 26, No. 2, 1989, pp. 280-283. doi:10.1002/ana.410260217
[45] M. Hallett, “Functional Reorganization after Lesions of the Human Brain: Studies with Transcranial Magnetic Stimulation,” Revue Neurologique Société de Neurologie de Paris, Vol. 157, No. 8-9, 2001, pp. 822-826.
[46] K. Minematsu, T. Yamaguchi and T. Omae, “‘Spectacular Shrinking Deficit’: Rapid Recovery from a Major Hemispheric Syndrome by Migration of an Embolus,” Neurology, Vol. 42, No. 1, 1992, pp. 157-162. doi:10.1212/WNL.42.1.157
[47] R. Mikulik, L. Dusek, M. D. Hill, E. Fulep, J. C. Grotta, M. Ribo, et al., “Pattern of Response of National Institutes of Health Stroke Scale Components to Early Recanalization in the CLOTBUST Trial,” Stroke, Vol. 41, No. 3, 2010, pp. 466-470. doi:10.1161/STROKEAHA.109.567263
[48] L. Tatu, T. Moulin, J. Bogousslavsky and H. Duvernoy, “Arterial Territories of the Human Brain: Cerebral Hemispheres,” Neurology, Vol. 50, No. 6, 1998, pp. 1699-1708. doi:10.1212/WNL.50.6.1699
[49] A. M. Demchuk and A. M. Buchan, “Predictors of Stroke Outcome,” Neurologic Clinics, Vol. 18, No. 2, 2000, pp. 455-473. doi:10.1016/S0733-8619(05)70202-4
[50] D. Strbian, T. Sairanen, K. Rantanen, K. Piironen, S. Atula, T. Tatlisumak, et al., “Characteristics and Outcome of Ischemic Stroke Patients Who Are Free of Symptoms at 24 Hours Following Thrombolysis,” Cerebrovascular Disease, Vol. 31, No. 1, 2010, pp. 37-42. doi:10.1159/000320263
[51] U. Fischer, M. Arnold, K. Nedeltchev, C. Brekenfeld, P. Ballinari, L. Remonda, et al., “NIHSS Score and Arteriographic Findings in Acute Ischemic Stroke,” Stroke, Vol. 36, No. 10, 2005, pp. 2121-2125. doi:10.1161/01.STR.0000182099.04994.fc
[52] J. Berrouschot, J. Rother, J. Glahn, T. Kucinski, J. Fiehler and G. Thomalla, “Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis with Tissue Plasminogen Activator in Very Old (> or =80 Years) Stroke Patients,” Stroke, Vol. 36, No. 11, 2005, pp. 2421-2425. doi:10.1161/01.STR.0000185696.73938.e0
[53] D. Toni, S. Lorenzano, G. Agnelli, D. Guidetti, G. Orlandi, A. Semplicini, et al., “Intravenous Thrombolysis with rt-PA in Acute Ischemic Stroke Patients Aged Older than 80 Years in Italy,” Cerebrovascular Disease, Vol. 25, No. 1-2, 2008, pp. 129-135. doi:10.1159/000112323
[54] N. K. Mishra, N. Ahmed, G. Andersen, J. A. Egido, P. J. Lindsberg, P. A. Ringleb, et al., “Thrombolysis in Very Elderly People: Controlled Comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive,” British Medical Journal, Vol. 341, 2010, c6046. doi:10.1136/bmj.c6046
[55] C. Blinzler, L. Breuer, H. B. Huttner, P. D. Schellinger, S. Schwab and M. Kohrmann, “Characteristics and Outcome of Patients with Early Complete Neurological Recovery after Thrombolysis for Acute Ischemic Stroke,” Cerebrovascular Disease, Vol. 31, No. 2, 2010, pp. 185-190. doi:10.1159/000321869
[56] J. Alvarez-Sabin, C. A. Molina, J. Montaner, J. F. Arenillas, R. Huertas, M. Ribo, et al., “Effects of Admission Hyperglycemia on Stroke Outcome in Reperfused Tissue Plasminogen Activator-Treated Patients,” Stroke, Vol. 34, No. 5, 2003, pp. 1235-1241. doi:10.1161/01.STR.0000068406.30514.31
[57] A. Y. Poppe, S. R. Majumdar, T. Jeerakathil, W. Ghali, A. M. Buchan and M. D. Hill, “Admission Hyperglycemia Predicts a Worse Outcome in Stroke Patients Treated with Intravenous Thrombolysis,” Diabetes Care, Vol. 32, No. 4, 2009, pp. 617-622. doi:10.2337/dc08-1754
[58] J. Putaala, T. Sairanen, A. Meretoja, P. J. Lindsberg, M. Tiainen, R. Liebkind, et al., “Post-Thrombolytic Hyperglycemia and 3-Month Outcome in Acute Ischemic Stroke,” Cerebrovascular Disease, Vol. 31, No. 1, 2010, pp. 83-92. doi:10.1159/000321332
[59] S. E. Capes, D. Hunt, K. Malmberg, P. Pathak and H. C. Gerstein, “Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients: A Systematic Overview,” Stroke, Vol. 32, No. 10, 2001, pp. 2426-2432. doi:10.1161/hs1001.096194
[60] A. Y. Poppe and M. D. Hill, “Hyperglycemia in Thrombolysed Acute Ischemic Stroke Patients,” International Journal of Stroke, Vol. 6, No. 3, 2011, p. 278.
[61] K. Huber, “Plasminogen Activator Inhibitor Type-1 (Part One): Basic Mechanisms, Regulation, and Role for Thromboembolic Disease,” Journal of Thrombosis and Thrombolysis, Vol. 11, No. 3, 2001, pp. 183-193. doi:10.1023/A:1011955018052
[62] K. Huber, “Plasminogen Activator Inhibitor Type-1 (Part Two): Role for Failure of Thrombolytic Therapy. PAI-1 Resistance as a Potential Benefit for New Fibrinolytic Agents,” Journal of Thrombosis and Thrombolysis, Vol. 11, No. 3, 2001, pp. 195-202. doi:10.1023/A:1011952602122
[63] S. C. Nicholls, E. K. Hoffer and W. L. Chandler, “Failure of Peripheral Arterial Thrombolysis Due to Elevated Plasminogen Activator Inhibitor Type 1,” Blood Coagulation & Fibrinolysis, Vol. 14, No. 8, 2003, pp. 729-733. doi:10.1097/00001721-200312000-00006
[64] D. J. Schneider, T. K. Nordt and B. E. Sobel, “Attenuated Fibrinolysis and Accelerated Atherogenesis in Type II Diabetic Patients,” Diabetes, Vol. 42, No. 1, 1993, pp. 1-7. doi:10.2337/diabetes.42.1.1
[65] Y. Zhu, P. Carmeliet and W. P. Fay, “Plasminogen Activator Inhibitor-1 Is a Major Determinant of Arterial Thrombolysis Resistance,” Circulation, Vol. 99, No. 23, 1999, pp. 3050-3055. doi:10.1161/01.CIR.99.23.3050
[66] W. D. Dietrich, O. Alonso and R. Busto, “Moderate Hyperglycemia Worsens Acute Blood-Brain Barrier Injury after Forebrain Ischemia in Rats,” Stroke, Vol. 24, No. 1, 1993, pp. 111-116. doi:10.1161/01.STR.24.1.111
[67] L. E. Allport, K. S. Butcher, T. A. Baird, L. MacGregor, P. M. Desmond, B. M. Tress, et al., “Insular Cortical Ischemia Is Independently Associated with Acute Stress Hyperglycemia,” Stroke, Vol. 35, No. 8, 2004, pp. 1886-1891. doi:10.1161/01.STR.0000133687.33868.71
[68] K. R. Lees, E. Bluhmki, R. von Kummer, T. G. Brott, D. Toni, J. C. Grotta, et al., “Time to Treatment with Intravenous Alteplase and Outcome in Stroke: An Updated Pooled Analysis of ECASS, ATLANTIS, NINDS, and EPITHET Trials,” Lancet, Vol. 375, No. 9727, 2010, pp. 1695-1703. doi:10.1016/S0140-6736(10)60491-6
[69] K. Kimura, K. Minematsu and T. Yamaguchi, “Atrial Fibrillation as a Predictive Factor for Severe Stroke and Early Death in 15,831 Patients with Acute Ischaemic Stroke,” Journal of Neurology, Neurosurgery & Psychiatry, Vol. 76, No. 5, 2005, pp. 679-683. doi:10.1136/jnnp.2004.048827
[70] G. D. Lowe, A. J. Jaap and C. D. Forbes, “Relation of Atrial Fibrillation and High Haematocrit to Mortality in Acute Stroke,” Lancet, Vol. 1, No. 8328, 1983, pp. 784-786. doi:10.1016/S0140-6736(83)91848-2
[71] K. Kimura, Y. Iguchi, K. Shibazaki, T. Iwanaga, S. Yamashita and J. Aoki, “IV t-PA Therapy in Acute Stroke Patients with Atrial Fibrillation,” Journal of the Neurological Sciences, Vol. 276, No. 1-2, 2009, pp. 6-8. doi:10.1016/j.jns.2008.10.018
[72] K. Kimura, Y. Iguchi, S. Yamashita, K. Shibazaki, K. Kobayashi and T. Inoue, “Atrial Fibrillation as an Independent Predictor for No Early Recanalization after IV-t-PA in Acute Ischemic Stroke,” Journal of the Neurological Sciences, Vol. 267, No. 1-2, 2008, pp. 57-61. doi:10.1016/j.jns.2007.09.036
[73] D. Sanak, R. Herzig, M. Kral, A. Bartkova, J. Zapletalova, M. Hutyra, et al., “Is Atrial Fibrillation Associated with Poor Outcome after Thrombolysis?” Journal of Neurology, Vol. 257, No. 6, 2010, pp. 999-1003. doi:10.1007/s00415-010-5452-4
[74] K. S. Hong and J. L. Saver, “Years of Disability-Adjusted Life Gained as a Result of Thrombolytic Therapy for Acute Ischemic Stroke,” Stroke, Vol. 41, No. 3, 2010, pp. 471-477. doi:10.1161/STROKEAHA.109.571083
[75] S. C. Fagan, “Stroke: Measuring Disease-Free Life after Thrombolysis,” Nature Reviews Neurology, Vol. 6, No. 7, 2010, pp. 361-362. doi:10.1038/nrneurol.2010.79
[76] S. Patel, R. Hughes, T. Hester, J. Stein, M. Akay, J. Dy, et al., “Tracking Motor Recovery in Stroke Survivors Undergoing Rehabilitation Using Wearable Technology,” Conference Proceedings of IEEE Engineering in Medicine and Biology Society, Vol. 2010, 2010, pp. 6858-6861.
[77] A. Parnandi, E. Wade and M. Mataric, “Motor Function Assessment Using Wearable Inertial Sensors,” Conference Proceedings of IEEE Engineering in Medicine and Biology Society, Vol. 2010, 2010, pp. 86-89.
[78] N. Gebruers C. Vanroy, S. Truijen, S. Engelborghs and P. P. De Deyn, “Monitoring of Physical Activity after Stroke: A Systematic Review of Accelerometry-Based Measures,” Archives of Physical Medicine and Rehabilitation, Vol. 91, No. 2, 2010, pp. 288-297. doi:10.1016/j.apmr.2009.10.025
[79] E. M. Siekierka-Kleiser, R. Kleiser, A. M. Wohlschlager, H. J. Freund and R. J. Seitz, “Quantitative Assessment of Recovery from Motor Hemineglect in Acute Stroke Patients,” Cerebrovascular Disease, Vol. 21, No. 5-6, 2006, pp. 307-214. doi:10.1159/000091535
[80] C. Calautti, P. S. Jones, N. Persaud, J. Y. Guincestre, M. Naccarato, E. A. Warburton, et al., “Quantification of Index Tapping Regularity after Stroke with Tri-Axial Accelerometry,” Brain Research Bulletin, Vol. 70, No. 1, 2006, pp. 1-7. doi:10.1016/j.brainresbull.2005.11.001
[81] N. Gebruers, S. Truijen, S. Engelborghs, G. Nagels, R. Brouns and P. P. De Deyn, “Actigraphic Measurement of Motor Deficits in Acute Ischemic Stroke,” Cerebrovascular Disease, Vol. 26, No. 5, 2008, pp. 533-540. doi:10.1159/000160210
[82] V. Reiterer, C. Sauter, G. Klosch, W. Lalouschek and J. Zeitlhofer, “Actigraphy—A Useful Tool for Motor Activity Monitoring in Stroke Patients,” European Neurology, Vol. 60, No. 6, 2008, pp. 285-291. doi:10.1159/000157882
[83] P. Lyden, “Tenecteplase for Acute Ischemic Stroke,” International Journal of Stroke, Vol. 6, No. 6, 2011, pp. 509-510. doi:10.1111/j.1747-4949.2011.00695.x
[84] D. F. Chapman, P. Lyden, P. A. Lapchak, S. Nunez, H. Thibodeaux and J. Zivin, “Comparison of TNK with WildType Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model,” Stroke, Vol. 32, No. 3, 2001, pp. 748-752. doi:10.1161/01.STR.32.3.748
[85] P. A. Lapchak, D. M. Araujo and J. A. Zivin, “Comparison of Tenecteplase with Alteplase on Clinical Rating Scores Following Small Clot Embolic Strokes in Rabbits,” Experimental Neurology, Vol. 185, No. 1, 2004, pp. 154-159. doi:10.1016/j.expneurol.2003.09.009
[86] C. P. Cannon, C. H. McCabe, C. M. Gibson, M. Ghali, R. F. Sequeira, G. R. McKendall, et al., “TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-Ranging Trial,” Circulation, Vol. 95, No. 2, 1997, pp. 351-356. doi:10.1161/01.CIR.95.2.351
[87] F. Van de Werf, C. P. Cannon, A. Luyten, K. Houbracken, C. H. McCabe, S. Berioli, et al., “Safety Assessment of Single-Bolus Administration of TNK Tissue-Plasminogen Activator in Acute Myocardial Infarction: The ASSENT1 Trial. The ASSENT-1 Investigators,” American Heart Journal, Vol. 137, No. 5, 1999, pp. 786-791. doi:10.1016/S0002-8703(99)70400-X
[88] F. Van De Werf, J. Adgey, D. Ardissino, P. W. Armstrong, P. Aylward, G. Barbash, et al., “Single-Bolus Tenecteplase Compared with Front-Loaded Alteplase in Acute Myocardial Infarction: The ASSENT-2 DoubleBlind Randomised Trial,” Lancet, Vol. 354, No. 9180, 1999, pp. 716-722. doi:10.1016/S0140-6736(99)07403-6
[89] M. W. Parsons, F. Miteff, G. A. Bateman, N. Spratt, A. Loiselle, J. Attia, et al., “Acute Ischemic Stroke: Imaging-Guided Tenecteplase Treatment in an Extended Time Window,” Neurology, Vol. 72, No. 10, 2009, pp. 915-921. doi:10.1212/01.wnl.0000344168.05315.9d
[90] G. J. del Zoppo, A. Ferbert, S. Otis, H. Bruckmann, W. Hacke, J. Zyroff, et al., “Local Intra-Arterial Fibrinolytic Therapy in Acute Carotid Territory Stroke. A Pilot Study,” Stroke, Vol. 19, No. 3, 1988, pp. 307-313. doi:10.1161/01.STR.19.3.307
[91] S. L. Barnwell, W. M. Clark, T. T. Nguyen, O. R. O’Neill, M. L. Wynn and B. M. Coull, “Safety and Efficacy of Delayed Intraarterial Urokinase Therapy with Mechanical Clot Disruption for Thromboembolic Stroke,” American Journal of Neuroradiology, Vol. 15, No. 10, 1994, pp. 1817-1822.
[92] G. J. del Zoppo, R. T. Higashida, A. J. Furlan, M. S. Pessin, H. A. Rowley and M. Gent, “PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery Stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism,” Stroke, Vol. 29, No. 1, 1998, pp. 4-11. doi:10.1161/01.STR.29.1.4
[93] A. Furlan, R. Higashida, L. Wechsler, M. Gent, H. Rowley, C. Kase, et al., “Intra-Arterial Prourokinase for Acute Ischemic Stroke. The PROACT II Study: A Randomized Controlled Trial. Prolyse in Acute Cerebral Thromboembolism,” Journal of the American Medical Association, Vol. 282, No. 21, 1999, pp. 2003-2011. doi:10.1001/jama.282.21.2003
[94] J. P. Broderick, “Endovascular Therapy for Acute Ischemic Stroke,” Stroke, Vol. 40, No. 3, 2009, pp. S103-S106. doi:10.1161/STROKEAHA.108.533067
[95] The IMS II Trial Investigators, “The Interventional Management of Stroke (IMS) II Study,” Stroke, Vol. 38, No. 7, 2007, pp. 2127-2135. doi:10.1161/STROKEAHA.107.483131
[96] J. D. Fields, K. Lindsay, K. C. Liu, G. M. Nesbit and H L. Lutsep, “Mechanical Thrombectomy for the Treatment of Acute Ischemic Stroke,” Expert Review of Cardiovascular Therapy, Vol. 8, No. 4, 2010, pp. 581-592. doi:10.1586/erc.10.8
[97] M. Rubiera, M. Ribo, J. Pagola, P. Coscojuela, D. Rodriguez-Luna, O. Maisterra, et al., “Bridging IntravenousIntra-Arterial Rescue Strategy Increases Recanalization and the Likelihood of a Good Outcome in Nonresponder Intravenous Tissue Plasminogen Activator-Treated Patients: A Case-Control Study,” Stroke, Vol. 42, No. 4, 2011, pp. 993-997. doi:10.1161/STROKEAHA.110.597104
[98] J. M. Wardlaw, V. Murray, E. Berge and G. J. Del Zoppo, “Thrombolysis for Acute Ischaemic Stroke,” Cochrane Database of Systematic Reviews, Vol. 4, 2009, CD00 0213.
[99] A. Frendl and L. Csiba, “Pharmacological and Non-Pharmacological Recanalization Strategies in Acute Ischemic Stroke,” Frontiers in Neurology, Vol. 2, 2011, p. 32. doi:10.3389/fneur.2011.00032
[100] S. Ansari, M. Rahman, M. F. Waters, B. L. Hoh and J. Mocco, “Recanalization Therapy for Acute Ischemic Stroke, Part 1: Surgical Embolectomy and Chemical Thrombolysis,” Neurosurgical Review, Vol. 34, No. 1, 2010, pp. 1-9. doi:10.1007/s10143-010-0293-2

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.